AI dual-stain approach improved accuracy, efficiency of cervical cancer screening
(NIH/National Cancer Institute) In a new study, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Pap test), the current standard for follow-up of women who test positive with primary human papillomavirus (HPV) screening. The algorithm was developed and the study conducted by investigators at the National Cancer Institute (NCI), part of the National Institutes of Health, in collaboration with researchers from several other institutions. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 25, 2020 Category: Cancer & Oncology Source Type: news
World First: Saliva Test Detects Occult HPV Oral Cancer World First: Saliva Test Detects Occult HPV Oral Cancer
A saliva test still under development has scored a world first: it led to a finding of oral cancer after detecting rising human papillomavirus DNA levels in subsequent oral rinses.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
Basel, 21 April 2020 - Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval for the cobas ® HPV test for use on the fully automated, high-throughput cobas® 6800/8800 Systems. The cobas® HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples. Persistent high-risk HPV infections can develop into pre cancerous lesions and, if left untreated, these lesions can progress to cervical cancer.“The approval of our HPV test for the cobas 6800 and 8800 Systems enables molec...
Source: Roche Media News - April 21, 2020 Category: Pharmaceuticals Source Type: news
Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer
Basel, 21 April 2020 - Roche (SIX: RO, ROG; OTCQX:RHHBY) today announced US Food and Drug Administration (FDA) approval for the cobas ® HPV test for use on the fully automated, high-throughput cobas® 6800/8800 Systems. The cobas® HPV test identifies women at risk for cervical cancer by detecting the presence of high-risk human papillomavirus (HPV) DNA in cervical samples. Persistent high-risk HPV infections can develop into p recancerous lesions and, if left untreated, these lesions can progress to cervical cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - April 21, 2020 Category: Pharmaceuticals Source Type: news
Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention
Basel, 11 March 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of CINtec®PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas ® 4800 HPV Test. This biomarker technology simplifies clinical decision making by providing easy to understand results so that clinicians and women are clear on next steps. The CINtecPLUS Cytology test identifies those women whose HPV infections are most likely to be associated with cervical pre-cancers. It enables c...
Source: Roche Media News - March 11, 2020 Category: Pharmaceuticals Source Type: news
Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention
Basel, 11 March 2020 — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced US Food and Drug Administration (FDA) approval of CINtec®PLUS Cytology as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas ® 4800 HPV Test. This biomarker technology simplifies clinical decision making by providing easy to understand results so that clinicians and women are clear on next steps. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2020 Category: Pharmaceuticals Source Type: news
Cancer-causing HPV can hit you even if you had the vaccination
Jessica Donald, from Birmingham, thought she'd get the all-clear after a cervical cancer screening test at her GP - only to be told she'd tested positive for human papillomavirus. (Pictured, stock image.) (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2020 Category: Consumer Health News Source Type: news
The incidence of oropharyngeal cancer and rate of human papillomavirus vaccination coverage in Florida, 2011 through 2015.
CONCLUSIONS:The authors found relatively higher and increasing incidence rate of OPC in Florida and lower rate of HPV vaccination among adolescents in Florida than in the nation overall.PRACTICAL IMPLICATIONS:The trends illustrated may stimulate policy changes to increase HPV vaccination for children and enhance the understanding of its benefits. (Source: Dental Technology Blog)
Source: Dental Technology Blog - January 22, 2020 Category: Dentistry Source Type: news
Cervical cancer could be on its way to extinction thanks to improved testing and vaccination
A new detection method rolled out last month looks for traces of the human papillomavirus (HPV), which cause nearly all cervical tumours. (Source: the Mail online | Health)
Source: the Mail online | Health - January 20, 2020 Category: Consumer Health News Source Type: news
Routine HPV Testing May Be Warranted for Sinonasal Cancers
FRIDAY, Jan. 3, 2020 -- Only one in four patients with sinonasal squamous cell carcinoma (SNSCC) is tested for human papillomavirus (HPV), according to a study published online Dec. 30 in Cancer.
Jamie R. Oliver, from the New York University School... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 3, 2020 Category: Pharmaceuticals Source Type: news
Improved Saliva Test Aids Detection of HPV-16 Improved Saliva Test Aids Detection of HPV-16
Use of acoustofluidic separation technology (AFS) doubles detection of oropharyngeal cancer-associated human papillomavirus-16 (HPV-OPC) in saliva, according to an international group of investigatorsReuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 27, 2019 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
HPV Genotyping and Reflex Cytology Efficient for Cervical-Cancer Screening HPV Genotyping and Reflex Cytology Efficient for Cervical-Cancer Screening
Human papillomavirus (HPV) genotyping for HPV-16 and HPV-18, followed by reflex cytological testing in women with positive results, is more likely than cytological testing alone to detect cervical intraepithelial neoplasia (CIN) grade 2 or higher, according to results from the FRIDA study.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 3, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news
Roche Packs New FDA-Approved Test in Its Arsenal
Roche has won a nod from FDA for a new diagnostic for individual blood donation testing. The Basel-Switzerland-based company’s cobas Babesia test is for use on the cobas 6800/8800 system.
Cobas Babesia detects parasites that live in red blood cells. Roche said this test is an important advancement because the Babesia parasite cannot be detected in traditional plasma or serum samples. The test can detect the four-common species of Babesia and employs the new whole blood collection tube, which simplifies Babesia sample preparation by consolidating steps within the tube itself to provide an efficient solutio...
Source: MDDI - September 20, 2019 Category: Medical Devices Authors: Omar Ford Tags: IVD Regulatory and Compliance Source Type: news
Confused About Who Should Get the HPV Vaccine, and When? The CDC Has New Recommendations
For its first few years on the market, the human papillomavirus (HPV) vaccine was approved only for young girls. Over time, the U.S. Food and Drug Administration (FDA) has broadened its approval to include boys, as well as adults up to age 45—allowing more people to get the cancer-preventing vaccine, but also breeding confusion about who should get vaccinated and when.
On Thursday, the U.S. Centers for Disease Control and Prevention (CDC) released new recommendations, based on guidance from the Advisory Committee on Immunization Practices, that should clear up some of that confusion. The CDC reaffirmed that its prior...
Source: TIME: Health - August 15, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized onetime public health Source Type: news
Why Sexually Transmitted Infections Can ’t Shake Their Stigma
We live in an era of sex positivity — until we get positive test results. And that’s unfortunate, because S.T.I.s are on the rise. (Source: NYT Health)
Source: NYT Health - August 13, 2019 Category: Consumer Health News Authors: Jen Gunter Tags: your-feed-selfcare Sexually Transmitted Diseases Herpes Viruses Human Papillomavirus (HPV) your-feed-science your-feed-health Source Type: news
